Our review focused on obesity-related outcomes associated with manipulation of or variation in three key enzymes: FAAH, an enzyme responsible for degradation of many bioactive lipids, especially AEA; MAGL, another enzyme responsible for degradation, especially 2-AG; and DAGL, an enzyme involved in the synthesis of 2-AG. The gene discussed is MGLL; the disease is Obesity.